Navigation Links
OrbusNeich's Genous™ Bio-engineered R stent™ Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease
Date:9/23/2010

WASHINGTON, Sept. 23 /PRNewswire/ -- OrbusNeich today announced that six-month follow-up clinical trial data demonstrate the excellent safety profile and efficacy of the company's Genous Bio-engineered R stent in combination with a paclitaxel-coated balloon for the treatment of de novo coronary artery disease. The data were presented by Jochen Woehrle, M.D., University of Ulm, Germany, principal investigator of the study, in the first report clinical trial session at Transcatheter Cardiovascular Therapeutics (TCT) 2010 in Washington.

The PERfECT STENT (A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients Treated with Endothelial Progenitor Cell Capturing Stents for De Novo Coronary Artery Disease) study compared the combination of a paclitaxel-coated balloon (SeQuent® Please, B. Braun) with a Genous stent to the Genous stent alone in 120 patients undergoing percutaneous coronary intervention (PCI).

The primary endpoint of the study was in-stent late loss at six months. Secondary endpoints included diameter stenosis, binary restenosis rate, target lesion revascularization (TLR), major adverse cardiac events (MACE) and stent thrombosis.

The in-stent late loss at six months follow-up of 0.34 mm was significantly lower in the patient group treated with the Genous stent in combination with a paclitaxel-coated balloon when compared to 0.88 mm in the control group. There was no definite and probable stent thrombosis reported in either arm of the study. Both patient groups received three months of dual antiplatelet therapy. In addition, the rates of TLR and MACE were lower in the investigational group compared to the control group.

"We are very encouraged by the good clinical and safety outcomes seen in patients treated with a combination of a paclitaxel-coated balloon and pro-healing technologies with only three months of dual antiplatelet therapy," said Professor Woehrle. "This study supports the company
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. 100 Percent Coverage of Struts and Complete Neointimal Coverage of OrbusNeichs Genous™ Bio-engineered R stent™ Demonstrated 26 Days Post-Implantation in STEMI Patient
2. Data Show OrbusNeichs Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon
3. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Excellent Safety and Clinical Outcomes in High-Risk Elderly Patients
4. Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
5. OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
6. Clinical Data Presented at Asia PCR/Sing LIVE Demonstrate Benefits of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) in Challenging Patient Subsets
7. Pre-clinical Data Show OrbusNeichs Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies
8. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2009
9. Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
10. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
11. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015  The recent flurry of PBM ... employer groups scrambling to identify a pharmacy benefit ... care plan, retail pharmacy chain, or other potentially ... purchase of Catamaran, Rite Aid,s $2 billion acquisition ... Omni-Care for $10 billion are just the latest ...
(Date:5/28/2015)... , May 28, 2015 The ... the Commission,s antitrust suit charging Cephalon, Inc. with ... drug Provigil. The settlement ensures that Teva Pharmaceutical ... make a total of $1.2 billion available to ... who overpaid because of Cephalon,s illegal conduct.  ...
(Date:5/28/2015)... BURNABY, British Columbia , May 28, 2015 ... company developing an intravenous catheter-based phrenic-nerve-pacing system announced ... Jefferies 2015 Global Healthcare Conference on Thursday, June ... PE will present at 11:30 a.m. Eastern Time.   ... Lungpacer Medical is a preclinical stage medical ...
Breaking Medicine Technology:Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 2Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 3FTC Settlement of Cephalon Pay for Delay Case Ensures $1.2 Billion in Ill-Gotten Gains Relinquished; Refunds Will Go To Purchasers Affected By Anticompetitive Tactics 2FTC Settlement of Cephalon Pay for Delay Case Ensures $1.2 Billion in Ill-Gotten Gains Relinquished; Refunds Will Go To Purchasers Affected By Anticompetitive Tactics 3
... new and innovative technology has enabled more and more ... office, the central laboratory is hardly threatened with extinction. ... are busier than ever before, and the huge range ... handle very large volumes of tests assures them an ...
... ,Contributing Editor , ,Appendicitis is a common, potentially ... their lives. The condition occurs when the appendix, ... becomes obstructed by mucus, stool, or lymphatic tissue. ... sepsis. The risk of these complications, already elevated ...
Cached Medicine Technology:Immunoassay Systems - Your Laboratory Workhorse 2Appendicitis: Evolving Tools to Diagnose a Classic Disease 2Appendicitis: Evolving Tools to Diagnose a Classic Disease 3
(Date:5/28/2015)... Baptist Medical Center Jacksonville has added ... acute stroke or other neurological conditions. , The new ... few in the country and the first in Florida ... as brain aneurysms. , “Baptist Health is committed ... who are impacted by stroke,” said Nicole Thomas, Baptist ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Real Time ... lotion and products, today announced their best-selling lotion is now ... Time Pain Relief is an FDA registered OTC pain relief ... herbal ingredients, such as Aloe Vera, Arnica, Capsicum, Chondroitin, Emu ... level of Menthol – only 1.25% – to avoid buildup ...
(Date:5/28/2015)... Hills, CA (PRWEB) May 28, 2015 ... novel interactive keratoconus web application to make ... has expanded in the last few years. This proliferation ... eye doctors are not aware of the nuances of ... Khanna Vision Institute, realized that websites can be boring ...
(Date:5/28/2015)... Optimity Advisors ( Optimity ) – ... care for healthcare organizations worldwide – today announced ... operationalize contracting and engagement models. As part of ... of seven “ OrangePapers” that provide actionable ... a strategy, operations and information technology advisory firm ...
(Date:5/28/2015)... 28, 2015 The drug epidemic has struck ... article published on May 12th, 2015, by Bradenton , ... of time. The first victim, Dylan Besser (21) was a ... the scene. The second overdose victim, Julian Toomsen-Hall (18) was ... the alarming overdose deaths on campus, the college has created ...
Breaking Medicine News(10 mins):Health News:Baptist Medical Center Jacksonville Adds Dedicated Neuro Emergency Unit 2Health News:Baptist Medical Center Jacksonville Adds Dedicated Neuro Emergency Unit 3Health News:Real Time Pain Relief Introduces New Four Ounce Pump Bottle for their Popular Pain Relief Lotion 2Health News:Dr.Khanna Announced the Release of an Interactive Web Application for Keratoconus Treatment 2Health News:Optimity Advisors Now Offers Outcomes Based Contracting Services to Support Engagement Model For New Healthcare Innovative Models of Care 2Health News:Two College Campus Deaths Force Sarasota College to Create Drug Task Force 2Health News:Two College Campus Deaths Force Sarasota College to Create Drug Task Force 3
... at Buffalo,s Research Institute on Addictions (RIA) is initiating ... used in behavioral medicine for stress reduction but not ... use disorders. , ... MBSR in alcoholism treatment, we hope to develop an ...
... testing company to license proprietary ... ... DGX ), the nation,s leading provider of diagnostic,testing, information and ... agreement for the heteroduplex tracking technology,underlying Pathway Diagnostics, SensiTrop(TM) HIV co-receptor ...
... care the hard way -- when they or a loved one needs ... term care is expensive; -- It is not covered under Medicare, ... and -- Medicaid will only pay for your long term care ... assets. Even then, Medicaid is heavily biased toward ...
... Fla., Oct. 26 In an effort to raise,awareness ... of U.S. News,& World Report will feature a cover ... a ranking of the nations, top 50 commercial,health plans, ... nations, best Medicare and,Medicaid plans. All the rankings are ...
... on anti-aging and ... personal beauty, ... launch of the first consumer website dedicated,to consumer reviews and expert ... in an,open and honest conversation about important decisions that affect the ...
... Oct. 26, 2007 11:00AM Adults with ... OROS methylphenidate HCl Extended-release Tablets showed significant improvements ... placebo, according to study results presented today at ... of children and adolescents with ADHD is clearly ...
Cached Medicine News:Health News:Dealing with stress as a treatment for alcohol abuse 2Health News:Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics 2Health News:Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics 3Health News:Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics 4Health News:Congress Declares 'Long Term Care Awareness Week' - Long Term Care Group, Inc. Continues Related Work 2Health News:Blue Cross and Blue Shield of Florida NCQA/U.S. News & World Report Ranking 2Health News:Consumers Open Up on RealSelf.com About 'Getting Work Done' 2Health News:Consumers Open Up on RealSelf.com About 'Getting Work Done' 3Health News:New study of Concerta showed significant improvement of ADHD symptom management in adults 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: